1513 — Livzon Pharmaceutical Share Price
- HK$26.50bn
- HK$20.21bn
- CNY12.43bn
- 91
- 72
- 98
- 99
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 10.31 | ||
PEG Ratio (f) | 1.09 | ||
EPS Growth (f) | 10.43% | ||
Dividend Yield (f) | 6.82% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.73 | ||
Price to Tang. Book | 1.85 | ||
Price to Free Cashflow | 8.44 | ||
Price to Sales | 2.01 | ||
EV to EBITDA | 8.1 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 16.37% | ||
Return on Equity | 14.56% | ||
Operating Margin | 21.62% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CNYm | 9,384.7 | 10,520.41 | 12,063.86 | 12,629.58 | 12,430.04 | 12,600.37 | 13,200.63 | 7% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +17.31 | +20.52 | +9.03 | +8.16 | +2.38 | +11.49 | +10.16 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
LIVZON PHARMACEUTICAL GROUP INC. is a China based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products include western medicine preparation such as gastrointestinal drugs, cardiovascular drugs and antimicrobial drugs and gonadotrophin drugs, Chinese medicine preparation, active pharmaceutical ingredient and intermediates, diagnostic reagents and equipments. The Company distributes its products in the domestic market and to overseas markets.
Directors
- Baoguo Zhu CHM (59)
- Yanggang Tang PRE (51)
- Guoxiang Xu VCH (58)
- Desheng Tao VCH (56)
- Yanxia Si FID (52)
- Liang Yang VPR (37)
- Yuxuan Huang VPR (54)
- Peng Xu VPR (64)
- Daihong Yang VPR (54)
- Peng Zhou VPR (57)
- Qingfeng Qiu NED (50)
- Xiong Yu NED (60)
- Hua Bai NID (52)
- Lijie Cui NID (45)
- Jinhua Huang NID (49)
- Huiyuan Luo NID (54)
- Qiusheng Tian NID (65)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- January 26th, 1985
- Public Since
- October 28th, 1993
- No. of Shareholders
- 46,754
- No. of Employees
- 8,933
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 926,608,853
- Address
- Livzon Mansion, ZHUHAI, 519090
- Web
- https://www.livzon.com.cn/
- Phone
- +86 7568135990
- Auditors
- Grant Thornton
Upcoming Events for 1513
Similar to 1513
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 21:49 UTC, shares in Livzon Pharmaceutical are trading at HK$28.60. This share price information is delayed by 15 minutes.
Shares in Livzon Pharmaceutical last closed at HK$28.60 and the price had moved by +16.02% over the past 365 days. In terms of relative price strength the Livzon Pharmaceutical share price has outperformed the FTSE Developed Asia Pacific Index by +2.94% over the past year.
The overall consensus recommendation for Livzon Pharmaceutical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Livzon Pharmaceutical dividend yield is 5.18% based on the trailing twelve month period.
Last year, Livzon Pharmaceutical paid a total dividend of CNY1.35, and it currently has a trailing dividend yield of 5.18%. We do not have any data on when Livzon Pharmaceutical is to next pay dividends.
We do not have data on when Livzon Pharmaceutical is to next pay dividends. The historic dividend yield on Livzon Pharmaceutical shares is currently 5.18%.
To buy shares in Livzon Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$28.60, shares in Livzon Pharmaceutical had a market capitalisation of HK$26.50bn.
Here are the trading details for Livzon Pharmaceutical:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1513
Based on an overall assessment of its quality, value and momentum Livzon Pharmaceutical is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Livzon Pharmaceutical is HK$29.15. That is 1.93% above the last closing price of HK$28.60.
Analysts covering Livzon Pharmaceutical currently have a consensus Earnings Per Share (EPS) forecast of CNY2.34 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Livzon Pharmaceutical. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +6.34%.
As of the last closing price of HK$28.60, shares in Livzon Pharmaceutical were trading +10.65% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Livzon Pharmaceutical PE ratio based on its reported earnings over the past 12 months is 10.31. The shares last closed at HK$28.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Livzon Pharmaceutical's management team is headed by:
- Baoguo Zhu - CHM
- Yanggang Tang - PRE
- Guoxiang Xu - VCH
- Desheng Tao - VCH
- Yanxia Si - FID
- Liang Yang - VPR
- Yuxuan Huang - VPR
- Peng Xu - VPR
- Daihong Yang - VPR
- Peng Zhou - VPR
- Qingfeng Qiu - NED
- Xiong Yu - NED
- Hua Bai - NID
- Lijie Cui - NID
- Jinhua Huang - NID
- Huiyuan Luo - NID
- Qiusheng Tian - NID